Literature DB >> 18714108

Neuropsychiatric disturbance after initiation of varenicline in a patient with a history of alcohol abuse and major depression.

Pejman Pirmoradi1, Susan Roshan, Sofia S Nadeem.   

Abstract

PURPOSE: The case of a patient with a history of alcohol abuse and major depression who developed neuropsychiatric symptoms after initiation of varenicline is reported.
SUMMARY: A 33-year-old Caucasian man was prescribed varenicline for smoking cessation. He had a history of hypertension, alcohol dependency, major depression, and hypothyroidism. The patient's only reported allergy was to morphine. The patient reported smoking four or five cigarettes daily for 10 years and discontinued alcohol use 2 years before varenicline initiation. He was prescribed varenicline 0.5 mg once daily; after three days, the dosage was increased to 0.5 mg twice daily, based on recommendations in the package insert. On the evening of the seventh day, after taking 10 doses of varenicline, the patient developed severe anxiety, nausea, vertigo, blurred vision, and dizziness. He reported to his physician's office where his blood pressure was 120/75 mm Hg and his heart rate was approximately 70 beats/min. His laboratory test results were unremarkable for liver and kidney dysfunction. Since the only recent change to his drug therapy was the initiation of varenicline, the drug was discontinued, after which his symptoms subsided gradually and completely disappeared after three days. The patient declined rechallenge with varenicline one week later. The patient's score on the Naranjo et al. adverse drug reaction probability scale was 6, indicating a probable relationship between treatment with varenicline and the patient's symptoms.
CONCLUSION: A patient with a history of alcohol dependence and major depression developed severe anxiety, nausea, vertigo, blurred vision, and dizziness after initiation of varenicline.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18714108     DOI: 10.2146/ajhp070641

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  9 in total

1.  Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis.

Authors:  Serena Tonstad; Simon Davies; Martina Flammer; Cristina Russ; John Hughes
Journal:  Drug Saf       Date:  2010-04-01       Impact factor: 5.606

2.  Smoking cessation after brain damage does not lead to increased depression: implications for understanding the psychiatric complications of varenicline.

Authors:  Daniel Tranel; Ashton McNutt; Antoine Bechara
Journal:  Cogn Behav Neurol       Date:  2012-03       Impact factor: 1.600

3.  Smoking outcome by psychiatric history after behavioral and varenicline treatment.

Authors:  Jennifer B McClure; Gary E Swan; Sheryl L Catz; Lisa Jack; Harold Javitz; Tim McAfee; Mona Deprey; Julie Richards; Susan M Zbikowski
Journal:  J Subst Abuse Treat       Date:  2010-04-02

Review 4.  Varenicline for tobacco dependence: panacea or plight?

Authors:  Jill M Williams; Michael B Steinberg; Marc L Steinberg; Kunal K Gandhi; Rajiv Ulpe; Jonathan Foulds
Journal:  Expert Opin Pharmacother       Date:  2011-06-06       Impact factor: 3.889

5.  A Review of Varenicline's Efficacy and Tolerability in Smoking Cessation Studies in Subjects with Schizophrenia.

Authors:  Mahtab Karkhane Yousefi; Timothy D Folsom; S Hossein Fatemi
Journal:  J Addict Res Ther       Date:  2011-12-20

Review 6.  Varenicline: a novel pharmacotherapy for smoking cessation.

Authors:  Carlos Jiménez-Ruiz; Ivan Berlin; Thomas Hering
Journal:  Drugs       Date:  2009-07-09       Impact factor: 9.546

Review 7.  Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation.

Authors:  Gillian M Keating; Katherine A Lyseng-Williamson
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

8.  Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline.

Authors:  Jennifer B McClure; Gary E Swan; Lisa Jack; Sheryl L Catz; Susan M Zbikowski; Tim A McAfee; Mona Deprey; Julie Richards; Harold Javitz
Journal:  J Gen Intern Med       Date:  2009-02-24       Impact factor: 5.128

9.  Pilot safety evaluation of varenicline for the treatment of methamphetamine dependence.

Authors:  Todd Zorick; Rajkumar J Sevak; Karen Miotto; Steven Shoptaw; Aimee-Noelle Swanson; Clayton Clement; Richard De La Garza; Thomas F Newton; Edythe D London
Journal:  J Exp Pharmacol       Date:  2009-12-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.